论文信息 - Administration of infliximab in Crohn's disease does not deplete complement components C3 and C4. - 字舞流文

Administration of infliximab in Crohn's disease does not deplete complement components C3 and C4.

Subrata Ghosh | I. Arnott | A. Shand

[1] S. Hanauer,et al. Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. , 1999, Inflammatory bowel diseases.

[2] Cooper,et al. Combination therapy of pentoxifylline and TNFα monoclonal antibody in dextran sulphate‐induced mouse colitis , 1999, Alimentary pharmacology & therapeutics.

[3] S. Targan,et al. A role for TNF-alpha and mucosal T helper-1 cytokines in the pathogenesis of Crohn's disease. , 1997, Journal of immunology.

[4] S. Targan,et al. A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease , 1997 .

[5] B. Scallon,et al. Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functions , 1995 .

[6] M. Nair,et al. Mutant p53 protein, Bcl-2/Bax ratios and apoptosis in paediatric acute lymphoblastic leukaemia , 2000, Journal of Cancer Research and Clinical Oncology.